Does heaven exist? With well over 100,000 plus recorded and described spiritual experiences collected over 15 years, to base the answer on, science can now categorically say yes. Furthermore, you can see the evidence for free on the website allaboutheaven.org.

Available on Amazon
also on all local Amazon sites, just change .com for the local version (.co.uk, .jp, .nl, .de, .fr etc.)


This book, which covers Visions and hallucinations, explains what causes them and summarises how many hallucinations have been caused by each event or activity. It also provides specific help with questions people have asked us, such as ‘Is my medication giving me hallucinations?’.

Available on Amazon
also on all local Amazon sites, just change .com for the local version (.co.uk, .jp, .nl, .de, .fr etc.)

Observations placeholder




Type of Spiritual Experience


Number of hallucinations: 247


A description of the experience

Memantine is marketed under the brands Axura and Akatinol by Merz, Namenda  by Forest, Ebixa and Abixa by Lundbeck and Memox by Unipharm. Quote “Despite years of research, whether memantine has any effect in mild to moderate AD is unknown.”

Memantine is the “first in a novel class of Alzheimer's disease medications acting on the glutamatergic system by blocking NMDA glutamate receptors”. In effect it is an NMDA receptor antagonist. But this is not all. Memantine acts as a non-competitive antagonist at the 5HT3 receptor, with a potency similar to that for the NMDA receptor. “The clinical significance of this serotonergic activity in the treatment of Alzheimer's disease is unknown”.

Memantine also acts as a non-competitive antagonist at different neuronal nicotinic acetylcholine receptors (nAChRs) “at potencies possibly similar to the NMDA and 5-HT3 receptors, but this is difficult to ascertain with accuracy because of the rapid desensitization of nAChR responses in experiments”. So it is an anticholinergic. And finally, as if this was not enough, Memantine acts as an agonist at the dopamine D2 receptor. 

Memantine is approved for treatment of moderate to severe Alzheimer's disease, and has now received a limited recommendation by the UK's National Institute for Clinical Excellence for patients who fail other treatment options. Within the new guidance memantine is recommended as an option for managing Alzheimer’s disease for people with: moderate Alzheimer’s disease who are intolerant of or have a contraindication to AChE (acetylcholinesterase) inhibitors or those with severe Alzheimer’s disease.

Memantine is also being tested for generalized anxiety disorder, epilepsy, opioid dependence, systemic lupus erythematosus, depression, obsessive compulsive disorder, Tourette Syndrome, problem gambling, attention-deficit hyperactivity disorder (ADHD), glaucoma, tinnitus, neuropathic pain including Complex Regional Pain Syndrome, pervasive developmental disorders, HIV associated dementia, nystagmus, multiple sclerosis and autism!

Common adverse drug reactions include confusion, dizziness, drowsiness, headache, insomnia, agitation, and/or hallucinations. Less common adverse effects include vomiting, anxiety, hypertonia, cystitis, and increased libido. It has been reported to induce reversible neurological impairment in multiple sclerosis patients, which led to the halt of an ongoing clinical trial. “ Though exceedingly rare, extrapyramidal side-effects (such as dystonic reactions, etc.) may occur, in particular, in the younger population” 

On Jan, 29, 2017 8,808 people reported to have side effects when taking Namenda.  Among them, 222 people (2.52%) have Hallucination

On Jan, 30, 2017 8,808 people reported to have side effects when taking Namenda.  Among them, 20 people (0.23%) have Hallucination, Auditory

On Jan, 05, 2017 8,808 people reported to have side effects when taking Namenda. Among them, 5 people (0.06%) have Hallucination, Olfactory


The source of the experience


Concepts, symbols and science items


Science Items

Activities and commonsteps


Hearing voices